Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in treatments for hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA), has announced its participation in the Bank of America Securities 2025 Health Care Conference. The event will be held in Las Vegas from May 12-15, 2025.
The company's management will deliver a presentation on Wednesday, May 14, 2025, at 4:35 PM PDT. Investors can access a live webcast of the presentation through the Investor Relations section of Mineralys' website. The presentation recording will remain available for approximately 90 days on the company's website.
Mineralys Therapeutics (NASDAQ: MLYS), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per ipertensione, malattia renale cronica (CKD) e apnea ostruttiva del sonno (OSA), ha annunciato la sua partecipazione alla Bank of America Securities 2025 Health Care Conference. L'evento si terrà a Las Vegas dal 12 al 15 maggio 2025.
Il management dell'azienda terrà una presentazione mercoledì 14 maggio 2025, alle 16:35 PDT. Gli investitori potranno seguire la presentazione in diretta streaming tramite la sezione Investor Relations del sito web di Mineralys. La registrazione della presentazione sarà disponibile sul sito per circa 90 giorni.
Mineralys Therapeutics (NASDAQ: MLYS), una compañía biofarmacéutica en etapa clínica especializada en tratamientos para hipertensión, enfermedad renal crónica (ERC) y apnea obstructiva del sueño (AOS), ha anunciado su participación en la Bank of America Securities 2025 Health Care Conference. El evento se llevará a cabo en Las Vegas del 12 al 15 de mayo de 2025.
La dirección de la compañía realizará una presentación el miércoles 14 de mayo de 2025 a las 4:35 PM PDT. Los inversores podrán acceder a la transmisión en vivo a través de la sección de Relaciones con Inversores en el sitio web de Mineralys. La grabación de la presentación estará disponible durante aproximadamente 90 días en el sitio web de la empresa.
Mineralys Therapeutics (NASDAQ: MLYS)는 고혈압, 만성 신장 질환(CKD), 폐쇄성 수면 무호흡증(OSA) 치료에 특화된 임상 단계 바이오제약 회사로, Bank of America Securities 2025 Health Care Conference에 참가한다고 발표했습니다. 행사는 2025년 5월 12일부터 15일까지 라스베이거스에서 개최됩니다.
회사의 경영진은 2025년 5월 14일 수요일 오후 4시 35분 PDT에 발표를 진행할 예정입니다. 투자자들은 Mineralys 웹사이트의 투자자 관계 섹션을 통해 생중계 웹캐스트를 시청할 수 있습니다. 발표 녹화 영상은 약 90일간 회사 웹사이트에 게시될 예정입니다.
Mineralys Therapeutics (NASDAQ : MLYS), une société biopharmaceutique en phase clinique spécialisée dans les traitements de l'hypertension, de la maladie rénale chronique (MRC) et de l'apnée obstructive du sommeil (AOS), a annoncé sa participation à la Bank of America Securities 2025 Health Care Conference. L'événement se tiendra à Las Vegas du 12 au 15 mai 2025.
La direction de la société présentera le mercredi 14 mai 2025 à 16h35 PDT. Les investisseurs pourront accéder à une diffusion en direct via la section Relations Investisseurs du site web de Mineralys. L'enregistrement de la présentation restera disponible environ 90 jours sur le site de la société.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Behandlungen von Bluthochdruck, chronischer Nierenerkrankung (CKD) und obstruktiver Schlafapnoe (OSA) spezialisiert hat, hat seine Teilnahme an der Bank of America Securities 2025 Health Care Conference bekannt gegeben. Die Veranstaltung findet vom 12. bis 15. Mai 2025 in Las Vegas statt.
Das Management des Unternehmens wird am Mittwoch, den 14. Mai 2025, um 16:35 Uhr PDT eine Präsentation halten. Investoren können die Präsentation live über den Investor-Relations-Bereich auf der Website von Mineralys verfolgen. Die Aufzeichnung der Präsentation wird etwa 90 Tage lang auf der Website verfügbar sein.
- None.
- None.
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025.
| Bank of America Securities Health Care Conference | ||
| Date: | Wednesday, May 14, 2025 | |
| Time: | 4:35pm PDT | |
| Format: | Presentation | |
| Webcast Link | ||
A live webcast of the presentation can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the presentation will be available on the Company’s website for approximately 90 days.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When is Mineralys Therapeutics (MLYS) presenting at the Bank of America Securities Health Care Conference 2025?
What diseases does Mineralys Therapeutics (MLYS) focus on treating?
How can investors access Mineralys Therapeutics' (MLYS) presentation at the BofA Healthcare Conference?
Where is the Bank of America Securities 2025 Health Care Conference being held?
